ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0530 • ACR Convergence 2024

    Long-term Effectiveness of a Lifestyle Intervention for Rheumatoid Arthritis: Two-year Follow-up After the “Plants for Joints” Randomized Clinical Trial

    Carlijn Wagenaar1, Wendy Walrabenstein2, Marike van der Leeden2, Franktien Turkstra2, Jos Twisk3, Maarten Boers3, Henriët van Middendorp4, Peter Weijs5 and Dirkjan van Schaardenburg6, 1Reade Rheumatology Center, Amsterdam, Netherlands, 2Reade Center for Rheumatology and Rehabilitation, Amsterdam, Netherlands, 3Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands, 4Leiden University, Leiden, Netherlands, 5Amsterdam University of Applied Sciences, Amsterdam, Netherlands, 6Amsterdam UMC, Amsterdam, Netherlands

    Background/Purpose: The 16-week Plants for Joints (PFJ) multidisciplinary lifestyle intervention, based on a whole-food plant-based diet, physical activity, and stress management, significantly reduced 28-joint Disease…
  • Abstract Number: 0801 • ACR Convergence 2024

    Neutrophil Activation as a Novel Marker of Lung Disease in Rheumatoid Arthritis

    Jia Shi1, Yang Wu1, Ting Wang2, Chen Yu3, qian wang4, Xinping Tian5, Mengtao Li4, Kristen Demoruelle6, Joshua Solomon7 and Christian Lood2, 1University of Washington, Seattle, 2University of Washington, Seattle, WA, 3Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Dong Cheng Qu, China (People's Republic), 4Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China, 5Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 6University of Colorado Anschutz Medical Campus, Golden, CO, 7National Jewish Health, Denver, CO

    Background/Purpose: Neutrophil activation is seen in rheumatoid arthritis (RA), but its involvement in RA interstitial lung disease (RA-ILD) is not clear. Levels of N-formyl methionine…
  • Abstract Number: 0894 • ACR Convergence 2024

    HOXD13 Regulation of Primary Cilia in Rheumatoid Arthritis Synovial Fibroblasts: Implications for Joint-Specific Pathogenesis

    Masoumeh Mirrahimi1, Kerstin Klein2, Alexandra Khmelevskaya3, Eva Camarillo Retamosa3, Miranda Houtmen3, Oliver Distler1 and Caroline Ospelt1, 1Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, 2University of Bern, Bern, Switzerland, 3Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Zurich, Switzerland

    Background/Purpose: Rheumatoid arthritis (RA) follows a characteristic pattern of joint involvement. The embryonic development of limbs and joints influences certain joints' propensity to develop arthritis.…
  • Abstract Number: 0945 • ACR Convergence 2024

    Involvement of Cellular Senescence in Rheumatoid Arthritis-associated Interstitial Lung Disease of SKG Mice

    Eri Watanabe1, Junko Nishio1, Tatsuma Ban2, Zento Yamada1, Tomohiko Tamura2 and Toshihiro Nanki1, 1Toho University, Tokyo, Japan, 2Yokohama City University, Yokohama, Japan

    Background/Purpose: There has been accumulating evidence that cellular senescence of fibroblasts and alveolar epithelial cells contributes to inflammation and fibrosis through a senescence-associated secretory phenotype…
  • Abstract Number: 1014 • ACR Convergence 2024

    Rural-dwelling Patients with Rheumatoid Arthritis or Those with Lower Income Are More Likely to Be Admitted for Myocardial Infarction in the U.S. and Have Worse Outcomes

    Sumanth Chandrupatla1 and Jasvinder Singh2, 1University of Alabama at Birmingham, Birmingham, AL, 2Baylor College of Medicine, Birmingham, AL

    Background/Purpose: We aimed to assess whether there is a rural-urban disparity in the incidence of myocardial infarction (MI) hospitalization in patients with rheumatoid arthritis (RA).Methods:…
  • Abstract Number: 1056 • ACR Convergence 2024

    Annual Cost of Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis

    Roya Hosseini1, Lawrence Brown1, Marc Fleming1, Rosa Rodriguez-Monguio2 and Enrique Seoane-Vazquez1, 1Chapman University School of Pharmacy, Irvine, CA, 2University of California San Francisco, San Francisco, CA

    Background/Purpose: Rheumatoid arthritis (RA) treatment has been revolutionized by the development of biologic disease-modifying antirheumatic drugs (bDMARDs), which are increasingly used. The high cost of…
  • Abstract Number: 1328 • ACR Convergence 2024

    Carpal Tunnel Syndrome Is an Early Unrecognized Feature of Rheumatoid Arthritis: A Population-Based Study

    Roslin Jose George1, Noah Frechette1, Iqra Javed1, Bradly Kimbrough2, Sara Achenbach3, Elena Joerns1, Vanessa Kronzer1, John Davis1, Cynthia Crowson1 and Elena Myasoedova1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic Rochester, Rochester, MN, 3Mayo Clinic, Rochester, Rochester, MN

    Background/Purpose: Carpal tunnel syndrome (CTS) is a common complication of rheumatoid arthritis (RA). However, the occurrence of CTS before RA and the effect of RA…
  • Abstract Number: 1344 • ACR Convergence 2024

    Forced Vital Capacity Trajectories and Risk of Lung Transplant and ILD-Related Mortality Among Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease

    Rathnam Venkat1, Keigo Hayashi2, Pierre-Antoine Juge3, Gregory McDermott2, Misti Paudel4, Xiaosong Wang5, Kathleen Vanni5, Emily Kowalski6, Grace Qian5, Katarina Bade6, Alene Saavedra6, Kevin Mueller6, Sung Hae Chang7, Paul Dellaripa6, Michael Weinblatt8, Nancy Shadick5, Tracy J Doyle9, Philippe Dieudé10 and Jeffrey Sparks11, 1Tufts University School of Medicine, Boston, MA, 2Brigham and Women’s Hospital, Brookline, MA, 3Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, 4Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 5Brigham and Women’s Hospital, Boston, MA, 6Brigham and Women's Hospital, Boston, MA, 7Brigham and Women's Hospital/Soonchunhyang University, College of Medicine, Boston, MA, 8Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, 9Brigham and Women's Hospital, West Roxbury, MA, 10Departement of Rheumatology, AP-HP, Bichat Hospital, Paris, France, 11Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA

    Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is heterogeneous with about half of patients having progressive disease. However, the rates of progression and the association…
  • Abstract Number: 1360 • ACR Convergence 2024

    Impact of Maintaining Low Disease Activity on Patient Outcomes and Healthcare Resource Utilization in Rheumatoid Arthritis Patients Receiving Advanced Treatment

    Urbano Sbarigia1, Jing Zhao2, Jackie Kwong2, Chinmayi Naik3, Federico Zazzetti4, Nancy Shadick3 and Michael Weinblatt5, 1Johnson & Johnson Innovative Medicine, Brussels, Belgium, 2Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, 3Brigham and Women’s Hospital, Boston, MA, 4Johnson & Johnson Innovative Medicine, Horsham, PA, PA, 5Brigham and Women's Hospital/ Harvard Medical School, Waban, MA

    Background/Purpose: Despite scientific advances and the availability of new treatments for rheumatoid arthritis (RA), many RA patients still cannot achieve the therapeutic goal of low…
  • Abstract Number: 1376 • ACR Convergence 2024

    Comparison of the Efficacy of DMARDs in Phase 3 Trials of Different Populations Used in FDA Approvals for Rheumatoid Arthritis Since 2010

    Catherine Emanuel1 and Ajay Aggarwal2, 1Aclaris Therapeutics Inc., St Louis, MO, 2Aclaris Therapeutics, Inc., Wellesley, MA

    Background/Purpose: Varying mechanisms of action are required to address the needs of rheumatoid arthritis patients with different levels of severity. Since 2010, all new FDA…
  • Abstract Number: 1393 • ACR Convergence 2024

    Relationship Between Disease Activity and Adverse Events in Rheumatoid Arthritis: An Integrated Post Hoc Analysis of Upadacitinib Phase 3 Trials

    Roy Fleischmann1, Zoltán Szekanecz2, Eduardo Mysler3, Kevin Winthrop4, Kunihiro Yamaoka5, Kirsten Famulla6, Yanna Song7, Birgit Kovacs7, Sander Strengholt8 and Gerd Burmester9, 1Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2University of Debrecen, Debrecen, Hungary, 3Organizacion Medica de Investigacion, Buenos Aires, AR, Buenos Aires, Argentina, 4School of Medicine, Oregon Health and Science University, Portland, OR, 5Kitasato University School of Medicine, Sagamihara, Japan, 6AbbVie Deutschland GmbH & Co. KG, Immunology, North Chicago, 7AbbVie, North Chicago, IL, 8AbbVie Inc., North Chicago, IL, 9Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: Patients with RA are at a heightened risk of developing significant adverse events (AEs) such as MACE, VTE, and serious infectious events (SIE). Limited…
  • Abstract Number: 1661 • ACR Convergence 2024

    Rheumatoid Arthritis Synovial Fibroblast Modulation of T Cell Activation

    Melissa Romoff1, Daniel Ramirez2, Edward Dicarlo3, Susan Goodman4, Alexander Rudenska5, Laura Donlin1 and Melanie Smith1, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Cartago, Costa Rica, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 4Hospital for Special Surgery, New York 10025, NY, 5Memorial Sloan Kettering Cancer Center, New York, NY

    Background/Purpose: In the rheumatoid arthritis (RA) joint, resident synovial fibroblasts (FLS) interact with infiltrating leukocytes. We previously identified a population of sublining FLS responsive to…
  • Abstract Number: 1743 • ACR Convergence 2024

    What Are the Benefits of Treating Rheumatoid Arthritis Patients to Remission After Achieving Low Disease Activity in Clinical Practice?

    Jing Zhao1, Urbano Sbarigia2, Jackie Kwong1, Chinmayi Naik3, Federico Zazzetti4, Nancy Shadick3 and Michael Weinblatt5, 1Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, 2Johnson & Johnson Innovative Medicine, Brussels, Belgium, 3Brigham and Women’s Hospital, Boston, MA, 4Johnson & Johnson Innovative Medicine, Horsham, PA, PA, 5Brigham and Women's Hospital/ Harvard Medical School, Waban, MA

    Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend low disease activity (LDA) as initial treatment goal with remission as a subsequent target whenever possible.…
  • Abstract Number: 1871 • ACR Convergence 2024

    A Seropositive RA Polygenic Risk Score Does Not Predict Progression to RA in an ACPA Positive Population

    Tada Vargas1, Lauren Vanderlinden2, Patrick Carry3, Kristen Demoruelle4, Marie Feser1, Katerina Kechris5, Jane Buckner6, William Robinson7, Gary Firestein8, Michael Holers1, Kevin Deane9 and Jill Norris10, 1Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 2Colorado School of Public Health, Monument, CO, 3Department of Orthopedics, University of Colorado School of Medicine, Aurora, CO, 4University of Colorado Anschutz Medical Campus, Golden, CO, 5Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, 6Benaroya Research Institute, Seattle, WA, 7Division of Immunology and Rheumatology, Stanford University, and VA Palo Alto Health Care System, Stanford, CA, 8University of California, San Diego, San Diego, CA, 9University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 10Colorado School of Public Health, Denver, CO

    Background/Purpose: Serum autoantibodies, such as ACPA and RF, are commonly detectable prior to the development of seropositive clinical RA; however, not all individuals with these…
  • Abstract Number: 1954 • ACR Convergence 2024

    Examination of Rehabilitation Referrals from Rheumatology Practices for Adults with Rheumatoid Arthritis in the RISE Registry: A Feasibility and Descriptive Study

    Louise Thoma1, Jing Li2 and Gabriela Schmajuk3, 1University of North Carolina, Chapel Hill, NC, 2University of California, San Francisco, San Francisco, CA, 3UCSF / SFVA, San Francisco, CA

    Background/Purpose: Adults with rheumatoid arthritis (RA) commonly report functional limitations, pain, and fatigue that contribute to diminished quality of life and limit participation in valued…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology